Cargando…

Considerations for use of direct oral anticoagulants in arterial disease

Cardiovascular diseases including coronary heart disease, stroke, and peripheral arterial disease were responsible for an estimated 18 million deaths in 2017. Despite advances in management over the past several decades, these patients continue to have substantial risk of subsequent cardiovascular e...

Descripción completa

Detalles Bibliográficos
Autores principales: Siegal, Deborah M., Anand, Sonia S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8162231/
https://www.ncbi.nlm.nih.gov/pubmed/34095731
http://dx.doi.org/10.1002/rth2.12502
_version_ 1783700667651588096
author Siegal, Deborah M.
Anand, Sonia S.
author_facet Siegal, Deborah M.
Anand, Sonia S.
author_sort Siegal, Deborah M.
collection PubMed
description Cardiovascular diseases including coronary heart disease, stroke, and peripheral arterial disease were responsible for an estimated 18 million deaths in 2017. Despite advances in management over the past several decades, these patients continue to have substantial risk of subsequent cardiovascular events. We provide a narrative review of randomized clinical trials evaluating direct oral anticoagulants (DOACs) for the treatment of acute coronary syndromes, noncardioembolic ischemic stroke, embolic stroke of undetermined source, and peripheral arterial disease. In these conditions, considerations for use of single antiplatelet therapy, dual antiplatelet therapy, or low‐dose DOACs used together with antiplatelet therapy are presented.
format Online
Article
Text
id pubmed-8162231
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-81622312021-06-03 Considerations for use of direct oral anticoagulants in arterial disease Siegal, Deborah M. Anand, Sonia S. Res Pract Thromb Haemost State of the Art Isth 2020 Cardiovascular diseases including coronary heart disease, stroke, and peripheral arterial disease were responsible for an estimated 18 million deaths in 2017. Despite advances in management over the past several decades, these patients continue to have substantial risk of subsequent cardiovascular events. We provide a narrative review of randomized clinical trials evaluating direct oral anticoagulants (DOACs) for the treatment of acute coronary syndromes, noncardioembolic ischemic stroke, embolic stroke of undetermined source, and peripheral arterial disease. In these conditions, considerations for use of single antiplatelet therapy, dual antiplatelet therapy, or low‐dose DOACs used together with antiplatelet therapy are presented. John Wiley and Sons Inc. 2021-05-28 /pmc/articles/PMC8162231/ /pubmed/34095731 http://dx.doi.org/10.1002/rth2.12502 Text en © 2021 The Authors. Research and Practice in Thrombosis and Haemostasis published by Wiley Periodicals LLC on behalf of International Society on Thrombosis and Haemostasis (ISTH) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle State of the Art Isth 2020
Siegal, Deborah M.
Anand, Sonia S.
Considerations for use of direct oral anticoagulants in arterial disease
title Considerations for use of direct oral anticoagulants in arterial disease
title_full Considerations for use of direct oral anticoagulants in arterial disease
title_fullStr Considerations for use of direct oral anticoagulants in arterial disease
title_full_unstemmed Considerations for use of direct oral anticoagulants in arterial disease
title_short Considerations for use of direct oral anticoagulants in arterial disease
title_sort considerations for use of direct oral anticoagulants in arterial disease
topic State of the Art Isth 2020
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8162231/
https://www.ncbi.nlm.nih.gov/pubmed/34095731
http://dx.doi.org/10.1002/rth2.12502
work_keys_str_mv AT siegaldeborahm considerationsforuseofdirectoralanticoagulantsinarterialdisease
AT anandsonias considerationsforuseofdirectoralanticoagulantsinarterialdisease